Literature DB >> 34626410

Role of HSPGs in Systemic Bacterial Infections.

Rafael S Aquino1, Kazutaka Hayashida1, Atsuko Hayashida1, Pyong Woo Park2,3.   

Abstract

Heparan sulfate proteoglycans (HSPGs) are at the forefront of host-microbe interactions. Cell surface HSPGs are thought to promote infection as attachment and internalization receptors for many bacterial pathogens and as soluble inhibitors of host immunity when released from the cell surface by ectodomain shedding. However, the importance of HSPG-pathogen interactions in vivo has yet to be clearly established. Here we describe several representative methods to study the role of HSPGs in systemic bacterial infections, such as bacteremia and sepsis. The overall experimental strategy is to use mouse models to establish the physiological significance of HSPGs, to determine the identity of HSPGs that specifically promote infection, and to define key structural features of HSPGs that enhance bacterial virulence in systemic infections.
© 2022. Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Bacteremia; Heparan sulfate; Heparin; Host defense; Proteoglycan; Sepsis; Syndecans

Mesh:

Substances:

Year:  2022        PMID: 34626410      PMCID: PMC8560348          DOI: 10.1007/978-1-0716-1398-6_46

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  63 in total

Review 1.  Functions of cell surface heparan sulfate proteoglycans.

Authors:  M Bernfield; M Götte; P W Park; O Reizes; M L Fitzgerald; J Lincecum; M Zako
Journal:  Annu Rev Biochem       Date:  1999       Impact factor: 23.643

2.  A comparison of critical care research funding and the financial burden of critical illness in the United States.

Authors:  Craig M Coopersmith; Hannah Wunsch; Mitchell P Fink; Walter T Linde-Zwirble; Keith M Olsen; Marilyn S Sommers; Kanwaljeet J S Anand; Kathryn M Tchorz; Derek C Angus; Clifford S Deutschman
Journal:  Crit Care Med       Date:  2012-04       Impact factor: 7.598

Review 3.  Severe sepsis and septic shock.

Authors:  Derek C Angus; Tom van der Poll
Journal:  N Engl J Med       Date:  2013-08-29       Impact factor: 91.245

Review 4.  Sepsis: a roadmap for future research.

Authors:  Jonathan Cohen; Jean-Louis Vincent; Neill K J Adhikari; Flavia R Machado; Derek C Angus; Thierry Calandra; Katia Jaton; Stefano Giulieri; Julie Delaloye; Steven Opal; Kevin Tracey; Tom van der Poll; Eric Pelfrene
Journal:  Lancet Infect Dis       Date:  2015-04-19       Impact factor: 25.071

5.  Sepsis definitions: time for change.

Authors:  Jean-Louis Vincent; Steven M Opal; John C Marshall; Kevin J Tracey
Journal:  Lancet       Date:  2013-03-02       Impact factor: 79.321

6.  Benchmarking the incidence and mortality of severe sepsis in the United States.

Authors:  David F Gaieski; J Matthew Edwards; Michael J Kallan; Brendan G Carr
Journal:  Crit Care Med       Date:  2013-05       Impact factor: 7.598

7.  Why have clinical trials in sepsis failed?

Authors:  John C Marshall
Journal:  Trends Mol Med       Date:  2014-02-24       Impact factor: 11.951

Review 8.  Sepsis-induced immune dysfunction: can immune therapies reduce mortality?

Authors:  Matthew J Delano; Peter A Ward
Journal:  J Clin Invest       Date:  2016-01-04       Impact factor: 14.808

Review 9.  Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy.

Authors:  Richard S Hotchkiss; Guillaume Monneret; Didier Payen
Journal:  Nat Rev Immunol       Date:  2013-11-15       Impact factor: 53.106

Review 10.  The enigma of sepsis.

Authors:  Niels C Riedemann; Ren-Feng Guo; Peter A Ward
Journal:  J Clin Invest       Date:  2003-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.